Recent Additions & Deletions to the Formulary

Date	Drug Name / Strength Ordered	Action	Description	Indication	Comments
May-01	Abacavir, lamivudine, zidovudine combination (Trizivir®) 300 mg/150 mg/300 mg	Added	combination anti-retroviral agent	HIV infection	Potential for serious hypersensitivity reaction
May-01	Abciximab (Reopro®) 2 mg/ml injection	Deleted	Fab fragment of chimeric human murine monoclonal antibody 7E3	Adjunct to percutaneous transluminal coronary angioplasty for prevention of acute ischemic complications	Replaced by eptifibatide (Integrilin®)
May-01	Eptifibatide (Integrilin®), 0.75 mg/mL (100 mL vials) and 2 mg/mL (10 mL and 100 mL vials)	Added	Peptide glycoprotein IIb/IIIa receptor antagonist (platelet aggregation inhibitor)	Adjunct to percutaneous coronary intervention, treatment of acute coronary syndrome.	Limited to cardiac cath lab or intensive care
May-01	Mesalamine (Asacol®) 400 mg enteric-coated tablets	Added	aminosalicylate anti-inflammatory	acute ulcerative colitis
May-01	Metaraminol (Aramine®), 10 mg/mL Available in 10 mL vials	Added	Sympathomimetic amine	Used a s a vasopressor for management of certain types of shock	Use with caution in patients on digoxin or MAOIs. Administered by IV infusion. IV Push under direct MD supervision only.
May-01	Pantoprazole (Protonix®), 40 mg vial	Added	Proton pump inhibitor	FDA approved only for short-term treatment of GERD in patients unable to take oral medication	Not for direct IV administration. Must be administered through a 1.2 micron inline filter

Find Another Drug

NIH Home Page | Clinical Center Home Page | Pharmacy Home Page